Abstract
The Asia Pacific (AP) region is diverse and dynamic. It comprises over 40 economies, with about 24 markets that are relatively more active in terms of promulgating and implementing regulations that impact the biopharmaceutical industry and advance drug development. Although many country- and territory-specific regulations, often driven by the local economy and market dynamics, exist, the overall trend in the AP region is toward international harmonization and global convergence. More markets are now participating in the International Council on Harmonization (ICH), and there is growing interest in identifying and incorporating best practices from competent regulatory agencies. These include expedited pathways to speed access to new medicines, and incentives and other means to encourage innovation. In this paper, we provide a summary of recent activities in select AP markets.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Opinion of the State Council on The Reform of Evaluation and Approval System for Drug and Medical Device. No. 44 Document. August 25, 2015, General Office of the State Council, China.
CFDA Town Hall DIA annual meeting, Chicago, June 18–22, 2017.
The Opinion on Deepening the Reform of the Review and Approval System and Encouraging the Innovation of Drugs and Medical Devices. October 2017, China General Office of the Communist Party and General Office of the State Council, China.
CFDA Decision on Adjusting the Management of Import Drugs Registration. October 10, 2017, CFDA, China. http://eng.sfda.gov.cn/WS03/CL0755/. Accessed May 30, 2018.
Protection of Drug Clinical Trial Data. http://samr.cfda.gov.cn/WS01/CL1843/. Accessed June 12, 2018.
http://cnda.cfda.gov.cn/WS04/CL2050/227852.html. Accessed June 18, 2018.
https://npcobserver.com/2018/03/14/a-guide-to-2018-state-council-institutional-reforms/. Accessed June 14, 2018.
China unveils cabinet reshuffle plan. http://www.xinhuanet.com/english/2018-03/13/c_137035527.htm. Accessed June 14, 2018.
CIRS R&D Briefing 62: New drug approvals in ICH countries 2007–2016. http://www.cirsci.org/wp-content/uploads/2018/05/CIRS-RD-Briefing-67-04052018_FINAL.pdf. Accessed June 12, 2018.
Strategy of Sakigake. MHLW, Japan. http://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/140729-01.html. Accessed May 30, 2018.
PMDA future perspectives in 2017 Global DIA annual meeting, 18-22 June, Chicago, 2017.
Conditional Early Approval System for Medicinal Products on 20 October 2017. http://pj.jiho.jp/servlet/pjh/regulatory/outline/1226590658349.html. Accessed May 30, 2018.
http://wwwhourei.mhlw.go.jp/hourei/. Accessed June 12, 2018.
Good Post-Marketing Study Practice. MHLW Ordinance No. 171, July 2017. https://search.e-gov.go.jp/servlet/Public?CLASSNAME=PCMMSTDETAIL&id=495170134&Mode=0. Accessed May 30, 2018.
Enactment of Development Support and Special Approval of Drug Act (Draft), 26-May-2016. http://www.mfds.go.kr/. Accessed May 30, 2018.
Draft Guideline on License and Evaluation of In Vitro Companion Diagnostic Devices. http://www.mfds.go.kr/. Published March 2017. Accessed May 30, 2018.
Priority review pathway for prescription medicines. TGA. Australia https://www.tga.gov.au/priority-review-pathway-prescription-medicines. Published July 2017. Accessed May 30, 2018.
Provisional approval pathway: Prescription medicines. https://www.tga.gov.au/provisional-approval-pathway-prescription-medicines. Accessed June 12, 2018.
Orphan drug reform. TGA, Australia. https://www.tga.gov.au/orphan-drug-program-reforms. Published July 2017. Accessed May 30, 2018.
New Drugs and Clinical Trials Rules. http://www.cdsco.nic.in/forms/ShowSearchResult.aspx?Search=clinical%20trial%20rule. Published February 2018. Accessed May 30, 2018.
Technical Committee Recommendation on 42nd meeting, September 25. CDGI, India. https://timesofindia.indiatimes.com/india/to-market-new-drugs-in-india-global-trials-must-include-indians/articleshow/61029119.cms. Accessed May 30, 2018.
TFDA perspectives in 2017 Global DIA annual meeting, June 18-22, 2017, Chicago.
Breakthrough designation regulation. http://regulation.cde.org.tw/doc_data_display?sid=2646&doctype2. Accessed May 30, 2018.
Pharmaceutical Affairs Act. https://www.lexology.com/library/detail.aspx?g=950198a2-86cd-4294-ba3f-e981fa7807d5. Accessed May 30, 2018.
ASEAN member states http://asean.org/asean/asean-member-states/. Accessed May 30, 2018.
ACCSG & PPWG. http://asean.org/?static_post=accsq-structure. Accessed May 30, 2018.
ASEAN joint assessment procedure for pharmaceutical products public announcement. http://npra.moh.gov.my/images/Announcement/2016/ASEAN-WHO-SIAHR_Joint_Assessments-Public_announcement-December_2016_rev2.docx. Accessed June 14, 2018.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Han, F.V., Weiss, K. Regulatory Trends in Drug Development in Asia Pacific. Ther Innov Regul Sci 53, 497–501 (2019). https://doi.org/10.1177/2168479018791539
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479018791539